Exhibit 99.1
(ILLUMINA LOGO)
                                                         Illumina, Inc
                                                         NR200427

Contacts:    Jay Flatley                                 Timothy Kish
             President & CEO                             Chief Financial Officer
             1.858.202.4501                              1.858.202.4508
             jflatley@illumina.com                       tkish@illumina.com


        ILLUMINA COMPLETES SALE OF SAN DIEGO FACILITIES FOR $42 MILLION
                AND ENTERS INTO LONG-TERM LEASEBACK ARRANGEMENT

             SALE WILL PROVIDE NET PROCEEDS IN EXCESS OF $15 MILLION

SAN DIEGO, CALIFORNIA, August 19, 2004 -- Illumina, Inc. (NASDAQ: ILMN)
announced today that it has completed the sale of its San Diego facilities,
consisting of several buildings and an undeveloped tract of land, and has
entered into an initial 10 year lease of these facilities. Sale proceeds were
$42 million. After payoff of a mortgage on the property and related transaction
expenses, the Company will receive net proceeds from the sale in excess of $15
million.

"We originally purchased this property to ensure that we had ample building
space on one campus to accommodate the development and manufacturing of our
products" stated Jay Flatley, Illumina President and CEO. "Our manufacturing and
product development processes have become so efficient, we no longer require the
extra building capacity, allowing us to convert these efficiencies into $15
million of additional cash without dilution to shareholders," added Flatley.

Illumina (www.illumina.com) is developing next-generation tools that permit
large-scale analysis of genetic variation and function. The Company's
proprietary BeadArray(TM) technology -- now used in leading genomics centers
around the world -- provides the throughput, cost effectiveness and flexibility
to enable researchers in the life sciences and pharmaceutical industries to
perform the billions of tests necessary to extract medically valuable
information from advances in genomics and proteomics. This information will
correlate genetic variation and gene function with particular disease states,
enhancing drug discovery, allowing diseases to be detected earlier and more
specifically, and permitting better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: this release may contain forward-looking statements that involve risks and
uncertainties. Among the important factors that could cause actual results to
differ materially from those in any forward-looking statements are the costs and
outcome of Illumina's litigation with Affymetrix, market acceptance of
Illumina's BeadArray-based products, Illumina's ability to fully develop and
commercialize its BeadArray technologies, the Company's ability to successfully
commercialize its integrated BeadLab and BeadStation systems for high-throughput
genetic analysis, to continue to attract and retain customers in its services
and oligonucleotide synthesis operations, to fully develop its BeadArray
technologies, to develop and deploy new gene expression profiling and proteomics
applications for its platform technology, to manufacture robust Sentrix(R)
arrays and Oligator(R) oligonucleotides, and other factors detailed in the
Company's filings with the Securities and Exchange Commission including its
recent filings on Forms 10-K and 10-Q or in information disclosed in public
conference calls, the date and time of which are released beforehand. Illumina
disclaims any intent or obligation to update these forward-looking statements
beyond the date of this release.


                                      # # #